Pulmonary manifestations of Sjögren syndrome, systemic lupus erythematosus, and mixed connective tissue disease

Rheumatic Disease Clinics of North America

Volumn 41, Issue 2, 2015, Pages 263-277

  Mira Avendano, Isabel C ^a   Abril, Andy ^a  

^a MAYO CLINIC   (United States)

Author keywords

Connective tissue disorders; Interstitial lung disease; Mixed connective tissue disease; Sj gren syndrome; Systemic lupus erythematosus

Indexed keywords

ACUTE REVERSIBLE HYPOXEMIA; ANTIPHOSPHOLIPID SYNDROME; BRONCHIOLITIS; BRONCHITIS; DEEP VEIN THROMBOSIS; DIFFUSE ALVEOLAR HEMORRHAGE; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG DISEASE; LYMPHOCYTIC INTERSTITIAL PNEUMONIA; MEDIASTINUM LYMPHADENOPATHY; MIXED CONNECTIVE TISSUE DISEASE; MULTILOCULAR THYMIC CYST; NONHODGKIN LYMPHOMA; PLEURA EFFUSION; PLEURISY; PNEUMONIA; PRIORITY JOURNAL; PSEUDOLYMPHOMA; PULMONARY AMYLOIDOSIS; PULMONARY HYPERTENSION; REVIEW; SHRINKING LUNG SYNDROME; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THYMIC LYMPHOID HYPERPLASIA; USUAL INTERSTITIAL PNEUMONIA; COMPLICATION; LUNG DISEASES;

HUMANS; LUNG DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIXED CONNECTIVE TISSUE DISEASE; SJOGREN'S SYNDROME;

EID: 84926211568     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2015.01.001     Document Type: Review

References (94)

1. Peri Y., Agmon-Levin N., Theodor E., et al. Sjogren's syndrome, the old and the new. Best Pract Res Clin Rheumatol 2012, 26(1):105-117.
2. Vitali C., Bombardieri S., Jonsson R., et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002, 61(6):554-558.
3. Hatron P.Y., Tillie-Leblond I., Launay D., et al. Pulmonary manifestations of Sjogren's syndrome. Presse Med 2011, 40(1 Pt 2):e49-e64.
4. Shiboski S.C., Shiboski C.H., Criswell L., et al. American College of Rheumatology classification criteria for Sjogren's syndrome: a data-driven, expert consensus approach in the Sjogren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012, 64(4):475-487.
5. Vitali C., Bootsma H., Bowman S.J., et al. Classification criteria for Sjogren's syndrome: we actually need to definitively resolve the long debate on the issue. Ann Rheum Dis 2013, 72(4):476-478.
6. Parke A.L. Pulmonary manifestations of primary Sjogren's syndrome. Rheum Dis Clin North Am 2008, 34(4):907-920. viii.
7. Mavragani C.P., Moutsopoulos H.M. The geoepidemiology of Sjogren's syndrome. Autoimmun Rev 2010, 9(5):A305-A310.
8. Nannini C., Jebakumar A.J., Crowson C.S., et al. Primary Sjogren's syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality. BMJ Open 2013, 3(11):e003569.
9. Constantopoulos S.H., Papadimitriou C.S., Moutsopoulos H.M. Respiratory manifestations in primary Sjogren's syndrome. A clinical, functional, and histologic study. Chest 1985, 88(2):226-229.
10. Kurumagawa T., Kobayashi H., Motoyoshi K. Potential involvement of subclinical Sjogren's syndrome in various lung diseases. Respirology 2005, 10(1):86-91.
11. Papathanasiou M.P., Constantopoulos S.H., Tsampoulas C., et al. Reappraisal of respiratory abnormalities in primary and secondary Sjogren's syndrome. A controlled study. Chest 1986, 90(3):370-374.
12. Deheinzelin D., Capelozzi V.L., Kairalla R.A., et al. Interstitial lung disease in primary Sjogren's syndrome. Clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med 1996, 154(3 Pt 1):794-799.
13. Gardiner P., Ward C., Allison A., et al. Pleuropulmonary abnormalities in primary Sjogren's syndrome. JRheumatol 1993, 20(5):831-837.
14. Franquet T., Gimenez A., Monill J.M., et al. Primary Sjogren's syndrome and associated lung disease: CT findings in 50 patients. AJR Am J Roentgenol 1997, 169(3):655-658.
15. Koyama M., Johkoh T., Honda O., et al. Pulmonary involvement in primary Sjogren's syndrome: spectrum of pulmonary abnormalities and computed tomography findings in 60 patients. JThorac Imaging 2001, 16(4):290-296.
16. Uffmann M., Kiener H.P., Bankier A.A., et al. Lung manifestation in asymptomatic patients with primary Sjogren syndrome: assessment with high resolution CT and pulmonary function tests. JThorac Imaging 2001, 16(4):282-289.
17. Garcia-Carrasco M., Ramos-Casals M., Rosas J., et al. Primary Sjogren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) 2002, 81(4):270-280.
18. Shi J.H., Liu H.R., Xu W.B., et al. Pulmonary manifestations of Sjogren's syndrome. Respiration 2009, 78(4):377-386.
19. Yazisiz V., Arslan G., Ozbudak I.H., et al. Lung involvement in patients with primary Sjogren's syndrome: what are the predictors?. Rheumatol Int 2010, 30(10):1317-1324.
20. Palm O., Garen T., Berge Enger T., et al. Clinical pulmonary involvement in primary Sjogren's syndrome: prevalence, quality of life and mortality-a retrospective study based on registry data. Rheumatology (Oxford) 2013, 52(1):173-179.
21. Egashira R., Kondo T., Hirai T., et al. CT findings of thoracic manifestations of primary Sjogren syndrome: radiologic-pathologic correlation. Radiographics 2013, 33(7):1933-1949.
22. Davidson B.K., Kelly C.A., Griffiths I.D. Ten year follow up of pulmonary function in patients with primary Sjogren's syndrome. Ann Rheum Dis 2000, 59(9):709-712.
23. Parambil J.G., Myers J.L., Lindell R.M., et al. Interstitial lung disease in primary Sjogren syndrome. Chest 2006, 130(5):1489-1495.
24. Papiris S.A., Maniati M., Constantopoulos S.H., et al. Lung involvement in primary Sjogren's syndrome is mainly related to the small airway disease. Ann Rheum Dis 1999, 58(1):61-64.
25. Meyer K.C., Raghu G., Baughman R.P., et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012, 185(9):1004-1014.
26. Soto-Cardenas M.J., Perez-De-Lis M., Bove A., et al. Bronchiectasis in primary Sjogren's syndrome: prevalence and clinical significance. Clin Exp Rheumatol 2010, 28(5):647-653.
27. Papiris S.A., Saetta M., Turato G., et al. CD4-positive T-lymphocytes infiltrate the bronchial mucosa of patients with Sjogren's syndrome. Am J Respir Crit Care Med 1997, 156(2 Pt 1):637-641.
28. Ryu J.H., Myers J.L., Swensen S.J. Bronchiolar disorders. Am J Respir Crit Care Med 2003, 168(11):1277-1292.
29. Aerni M.R., Vassallo R., Myers J.L., et al. Follicular bronchiolitis in surgical lung biopsies: clinical implications in 12 patients. Respir Med 2008, 102(2):307-312.
30. Kreider M., Highland K. Pulmonary involvement in Sjogren syndrome. Semin Respir Crit Care Med 2014, 35(2):255-264.
31. Stojan G., Baer A.N., Danoff S.K. Pulmonary manifestations of Sjogren's syndrome. Curr Allergy Asthma Rep 2013, 13(4):354-360.
32. Ito I., Nagai S., Kitaichi M., et al. Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med 2005, 171(6):632-638.
33. Sarkar P.K., Patel N., Furie R.A., et al. Pulmonary manifestations of primary Sjogren's syndrome. Indian J Chest Dis Allied Sci 2009, 51(2):93-101.
34. Cha S.I., Fessler M.B., Cool C.D., et al. Lymphoid interstitial pneumonia: clinical features, associations and prognosis. Eur Respir J 2006, 28(2):364-369.
35. Liebow A.A., Carrington C.B. Diffuse pulmonary lymphoreticular infiltrations associated with dysproteinemia. Med Clin North Am 1973, 57(3):809-843.
36. Kauppi M., Pukkala E., Isomaki H. Elevated incidence of hematologic malignancies in patients with Sjogren's syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 1997, 8(2):201-204.
37. Voulgarelis M., Dafni U.G., Isenberg D.A., et al. Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. Arthritis Rheum 1999, 42(8):1765-1772.
38. Theander E., Henriksson G., Ljungberg O., et al. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis 2006, 65(6):796-803.
39. Hansen L.A., Prakash U.B., Colby T.V. Pulmonary lymphoma in Sjogren's syndrome. Mayo Clin Proc 1989, 64(8):920-931.
40. Rajagopala S., Singh N., Gupta K., et al. Pulmonary amyloidosis in Sjogren's syndrome: a case report and systematic review of the literature. Respirology 2010, 15(5):860-866.
41. Teshigawara K., Kakizaki S., Horiya M., et al. Primary Sjogren's syndrome complicated by bilateral pleural effusion. Respirology 2008, 13(1):155-158.
42. Launay D., Hachulla E., Hatron P.Y., et al. Pulmonary arterial hypertension: a rare complication of primary Sjogren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore) 2007, 86(5):299-315.
43. Kobak S., Kalkan S., Kirilmaz B., et al. Pulmonary arterial hypertension in patients with primary Sjogren's syndrome. Autoimmune Dis 2014, 2014:710401.
44. Gottenberg J.E., Cinquetti G., Larroche C., et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the autoimmune and rituximab registry. Ann Rheum Dis 2013, 72(6):1026-1031.
45. Fischer A., Brown K.K., Du Bois R.M., et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. JRheumatol 2013, 40(5):640-646.
46. Travis W.D., Colby T.V., Koss M.N., et al. Non-neoplastic disorders of the lower respiratory tract. 1st edition. AFIP Atlas of Nontumor Pathology 2002, American Registry of Pathology and the Armed Forces Institute of Pathology, Washington (DC).
47. Kim J.S., Lee K.S., Koh E.M., et al. Thoracic involvement of systemic lupus erythematosus: clinical, pathologic, and radiologic findings. JComput Assist Tomogr 2000, 24(1):9-18.
48. Murin S., Wiedemann H.P., Matthay R.A. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med 1998, 19(4):641-665. viii.
49. Orens J.B., Martinez F.J., Lynch J.P. Pleuropulmonary manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am 1994, 20(1):159-193.
50. Cervera R., Khamashta M.A., Font J., et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on systemic lupus erythematosus. Medicine (Baltimore) 1993, 72(2):113-124.
51. Carmier D., Marchand-Adam S., Diot P., et al. Respiratory involvement in systemic lupus erythematosus. Rev Mal Respir 2008, 25(10):1289-1303.
52. Keane M.P., Lynch J.P. Pleuropulmonary manifestations of systemic lupus erythematosus. Thorax 2000, 55(2):159-166.
53. Memet B., Ginzler E.M. Pulmonary manifestations of systemic lupus erythematosus. Semin Respir Crit Care Med 2007, 28(4):441-450.
54. Torre O., Harari S. Pleural and pulmonary involvement in systemic lupus erythematosus. Presse Med 2011, 40(1 Pt 2):e19-e29.
55. Wang D.Y., Yang P.C., Yu W.L., et al. Serial antinuclear antibodies titre in pleural and pericardial fluid. Eur Respir J 2000, 15(6):1106-1110.
56. Wiedemann H.P., Matthay R.A. Pulmonary manifestations of systemic lupus erythematosus. JThorac Imaging 1992, 7(2):1-18.
57. Ewan P.W., Jones H.A., Rhodes C.G., et al. Detection of intrapulmonary hemorrhage with carbon monoxide uptake. Application in Goodpasture's syndrome. NEngl J Med 1976, 295(25):1391-1396.
58. Inoue T., Kanayama Y., Ohe A., et al. Immunopathologic studies of pneumonitis in systemic lupus erythematosus. Ann Intern Med 1979, 91(1):30-34.
59. Boulware D.W., Hedgpeth M.T. Lupus pneumonitis and anti-SSA(Ro) antibodies. JRheumatol 1989, 16(4):479-481.
60. Mochizuki T., Aotsuka S., Satoh T. Clinical and laboratory features of lupus patients with complicating pulmonary disease. Respir Med 1999, 93(2):95-101.
61. Matthay R.A., Schwarz M.I., Petty T.L., et al. Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore) 1975, 54(5):397-409.
62. Isbister J.P., Ralston M., Hayes J.M., et al. Fulminant lupus pneumonitis with acute renal failure and RBC aplasia. Successful management with plasmapheresis and immunosuppression. Arch Intern Med 1981, 141(8):1081-1083.
63. Winder A., Molad Y., Ostfeld I., et al. Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases. JRheumatol 1993, 20(3):495-498.
64. Eiser A.R., Shanies H.M. Treatment of lupus interstitial lung disease with intravenous cyclophosphamide. Arthritis Rheum 1994, 37(3):428-431.
65. Fenlon H.M., Doran M., Sant S.M., et al. High-resolution chest CT in systemic lupus erythematosus. AJR Am J Roentgenol 1996, 166(2):301-307.
66. Eichacker P.Q., Pinsker K., Epstein A., et al. Serial pulmonary function testing in patients with systemic lupus erythematosus. Chest 1988, 94(1):129-132.
67. Devaraj A., Wells A.U., Hansell D.M. Computed tomographic imaging in connective tissue diseases. Semin Respir Crit Care Med 2007, 28(4):389-397.
68. Tansey D., Wells A.U., Colby T.V., et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004, 44(6):585-596.
69. Gammon R.B., Bridges T.A., al-Nezir H., et al. Bronchiolitis obliterans organizing pneumonia associated with systemic lupus erythematosus. Chest 1992, 102(4):1171-1174.
70. Takada H., Saito Y., Nomura A., et al. Bronchiolitis obliterans organizing pneumonia as an initial manifestation in systemic lupus erythematosus. Pediatr Pulmonol 2005, 40(3):257-260.
71. Langford C.A., Van Waes C. Upper airway obstruction in the rheumatic diseases. Rheum Dis Clin North Am 1997, 23(2):345-363.
72. Smith G.A., Ward P.H., Berci G. Laryngeal lupus erythematosus. JLaryngol Otol 1978, 92(1):67-73.
73. Teitel A.D., MacKenzie C.R., Stern R., et al. Laryngeal involvement in systemic lupus erythematosus. Semin Arthritis Rheum 1992, 22(3):203-214.
74. Andonopoulos A.P., Constantopoulos S.H., Galanopoulou V., et al. Pulmonary function of nonsmoking patients with systemic lupus erythematosus. Chest 1988, 94(2):312-315.
75. Prabu A., Patel K., Yee C.S., et al. Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus. Rheumatology (Oxford) 2009, 48(12):1506-1511.
76. Badesch D.B., Raskob G.E., Elliott C.G., et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010, 137(2):376-387.
77. Chung L., Liu J., Parsons L., et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010, 138(6):1383-1394.
78. Ahmed S., Palevsky H.I. Pulmonary arterial hypertension related to connective tissue disease: a review. Rheum Dis Clin North Am 2014, 40(1):103-124.
79. Pego-Reigosa J.M., Medeiros D.A., Isenberg D.A. Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best Pract Res Clin Rheumatol 2009, 23(4):469-480.
80. Henderson L.A., Loring S.H., Gill R.R., et al. Shrinking lung syndrome as a manifestation of pleuritis: a new model based on pulmonary physiological studies. JRheumatol 2013, 40(3):273-281.
81. Bull T.M., Fagan K.A., Badesch D.B. Pulmonary vascular manifestations of mixed connective tissue disease. Rheum Dis Clin North Am 2005, 31(3):451-464. vi.
82. Sciascia S., Lopez-Pedrera C., Roccatello D., et al. Catastrophic Antiphospholipid syndrome (CAPS). Best Pract Res Clin Rheumatol 2012, 26:535-541.
83. Cartin-Ceba R., Peikert T., Ashrani A.I., et al. Primary antiphospholipid syndrome-associated diffuse alveolar hemorrhage. Arthritis Care Res (Hoboken) 2014, 66(2):301-310.
84. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). JThromb Haemost 2006, 4(2):295-306.
85. Abramson S.B., Dobro J., Eberle M.A., et al. Acute reversible hypoxemia in systemic lupus erythematosus. Ann Intern Med 1991, 114(11):941-947.
86. Sharp G.C., Irvin W.S., Tan E.M., et al. Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972, 52(2):148-159.
87. Alarcon-Segovia D., Cardiel M.H. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. JRheumatol 1989, 16(3):328-334.
88. Ortega-Hernandez O.D., Shoenfeld Y. Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment. Best Pract Res Clin Rheumatol 2012, 26(1):61-72.
89. Hant F.N., Herpel L.B., Silver R.M. Pulmonary manifestations of scleroderma and mixed connective tissue disease. Clin Chest Med 2010, 31(3):433-449.
90. Gunnarsson R., Aalokken T.M., Molberg O., et al. Prevalence and severity of interstitial lung disease in mixed connective tissue disease: a nationwide, cross-sectional study. Ann Rheum Dis 2012, 71(12):1966-1972.
91. Gutsche M., Rosen G.D., Swigris J.J. Connective tissue disease-associated interstitial lung disease: a review. Curr Respir Care Rep 2012, 1:224-232.
92. Szodoray P., Hajas A., Kardos L., et al. Distinct phenotypes in mixed connective tissue disease: subgroups and survival. Lupus 2012, 21(13):1412-1422.
93. Olson A.L., Brown K.K., Fischer A. Connective tissue disease-associated lung disease. Immunol Allergy Clin North Am 2012, 32(4):513-536.
94. Hosoda Y., Suzuki Y., Takano M., et al. Mixed connective tissue disease with pulmonary hypertension: a clinical and pathological study. JRheumatol 1987, 14(4):826-830.